A potential new agent for the treatment of fungal skin infections
Destiny Pharma has announced new data on one of its compounds, XF-70, which has demonstrated potency in an in vivo model of ringworm, a common fungal skin infection, which affects up to one in four people worldwide. Ringworm is caused by a class of fungi called… Read More